Mibefradil
General information:
| Withdrawn ID: | DB01388 |
|---|---|
| Canonical SMILES: | |
| Standard InChI: | |
| Standard InChIKey: | |
| ATC class(es): | C08CX01 |
| Molecular Formula: | C29H38FN3O3 |
| Molweight: | 495.629 |
Withdrawal information:
| Withdrawn due to drug safety reasons: | No |
|---|---|
| First approved: | 1997 |
| First death: | 1998 |
| First withdrawn: | 1998 |
| Last withdrawn: | 1998 |
Side-effects:
| Total reported cases (submitted by medical professionals) with Mibefradil as primary suspect: | 1 |
|---|
Reported final outcomes:
| Hospitalization (initial or prolonged): | 1 |
|---|
Reported side-effects:
| Side-effect | Case number |
|---|---|
| DEPRESSION | 1 |
| CEREBRAL HAEMORRHAGE | 1 |
| CEREBROVASCULAR ACCIDENT | 1 |
| CHEST X-RAY ABNORMAL | 1 |
| CONFUSIONAL STATE | 1 |
| COUGH | 1 |
| CYANOSIS | 1 |
| DEMENTIA ALZHEIMER'S TYPE | 1 |
| DEPRESSED LEVEL OF CONSCIOUSNESS | 1 |
| CEREBRAL ATROPHY | 1 |
| DIABETIC KETOACIDOSIS | 1 |
| DIFFICULTY IN WALKING | 1 |
| DIZZINESS | 1 |
| DYSPNOEA | 1 |
| FALL | 1 |
| FATIGUE | 1 |
| FLIGHT OF IDEAS | 1 |
| GAIT DISTURBANCE | 1 |
| ATRIOVENTRICULAR BLOCK COMPLETE | 1 |
| ACQUIRED DIAPHRAGMATIC EVENTRATION | 1 |
| AGITATION | 1 |
| AMNESIA | 1 |
| ANXIETY | 1 |
| ARRHYTHMIA | 1 |
| ARTHRALGIA | 1 |
| ATELECTASIS | 1 |
| ATRIAL BIGEMINY | 1 |
| HAEMORRHAGE | 1 |
| ATRIOVENTRICULAR BLOCK SECOND DEGREE | 1 |
| BALANCE DISORDER | 1 |
| BLOOD CHOLESTEROL INCREASED | 1 |
| BRADYCARDIA | 1 |
| BUNDLE BRANCH BLOCK RIGHT | 1 |
| BUTTOCK PAIN | 1 |
| CARDIOMEGALY | 1 |
| CEREBRAL ARTERY STENOSIS | 1 |
| RENAL TUBULAR NECROSIS | 1 |
| NODAL ARRHYTHMIA | 1 |
| OEDEMA PERIPHERAL | 1 |
| PHARYNGOLARYNGEAL PAIN | 1 |
| POLLAKIURIA | 1 |
| PULMONARY CONGESTION | 1 |
| RED BLOOD CELL COUNT DECREASED | 1 |
| RENAL FAILURE | 1 |
| RENAL FAILURE ACUTE | 1 |
| NOCTURIA | 1 |
| RESPIRATORY ARREST | 1 |
| RESPIRATORY FAILURE | 1 |
| RHABDOMYOLYSIS | 1 |
| SEPSIS | 1 |
| SPUTUM DISCOLOURED | 1 |
| TREATMENT NONCOMPLIANCE | 1 |
| URINARY RETENTION | 1 |
| URINARY TRACT INFECTION | 1 |
| MALIGNANT HYPERTENSION | 1 |
| HEMIPARESIS | 1 |
| HYPERGLYCAEMIA | 1 |
| HYPERTENSION | 1 |
| HYPOAESTHESIA | 1 |
| HYPOTENSION | 1 |
| INCONTINENCE | 1 |
| LACTIC ACIDOSIS | 1 |
| LACUNAR INFARCTION | 1 |
| URINARY TRACT INFECTION FUNGAL | 1 |
| MENTAL STATUS CHANGES | 1 |
| METABOLIC ACIDOSIS | 1 |
| METABOLIC ENCEPHALOPATHY | 1 |
| MITRAL VALVE INCOMPETENCE | 1 |
| MYOCARDIAL INFARCTION | 1 |
| MYOCARDIAL ISCHAEMIA | 1 |
| NASAL CONGESTION | 1 |
| NASOPHARYNGITIS | 1 |
Filtered ChEMBL targets:
| Target UniProtKB ID | Activity in nm | Target Name | Target gene |
|---|---|---|---|
| O43497 | 64 | Voltage-dependent T-type calcium channel subunit alpha-1G | CAC1G_HUMAN |
| O95180 | 130 | Voltage-dependent T-type calcium channel subunit alpha-1H | CAC1H_HUMAN |
| P10636 | 4466.8 | Microtubule-associated protein tau | TAU_HUMAN |
| Q12809 | 190 | Potassium voltage-gated channel subfamily H member 2 | KCNH2_HUMAN |
| Q13936 | 202 | Voltage-dependent L-type calcium channel subunit alpha-1C | CAC1C_HUMAN |
| Q14524 | 500 | Sodium channel protein type 5 subunit alpha | SCN5A_HUMAN |
| Q15858 | 500 | Sodium channel protein type 9 subunit alpha | SCN9A_HUMAN |
| Q9P0X4 | 130 | Voltage-dependent T-type calcium channel subunit alpha-1I | CAC1I_HUMAN |
Toxicity information:
| Toxicity class: | 4 |
|---|---|
| Toxicity type: | N/A |
| LD50: | 800 mg/kg |
External links:
| ChEBML: | CHEMBL45816 |
|---|---|
| DrugBank: | DB01388 |